ArticleJournal of medical ethics2020
Ethics and ego dissolution: the case of psilocybin.
Article in Journal of medical ethics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis.BMC psychology · 2026Pooled it
- The need for another tool: Australian healthcare professionals on the use of psilocybin for existential distress in people with cancer.BMC medicine · 2026Article
- Facing trauma under the influence of psychedelics: A phenomenological study with Nova rave survivors.Journal of psychopharmacology (Oxford, England) · 2026Article
- Toward a framework for psychedelic clinical trials in adolescents.Child and adolescent psychiatry and mental health · 2026Review
- Ethical Issues and Recommendations in Psychedelic Research and Practice: A Scoping Review.Journal of bioethical inquiry · 2026Article
- Article
- Synergies in psychedelic-assisted therapy: a qualitative interview study of psychotherapeutic processes.Frontiers in psychiatry · 2026Article
- Ritual to relief: ethical frontiers in repurposing psychoactive substances.CNS spectrums · 2025Review
- Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.EClinicalMedicine · 2025Review
- Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.Psychological medicine · 2025Article
- The Ethics of Set and Setting in Psychedelic Psychotherapy.Neuroethics · 2025Article
- History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers.Journal of bioethical inquiry · 2025Article
- The Emergence of Psilocybin in Psychiatry and Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.Therapeutic advances in psychopharmacology · 2025Article
- On Minimizing Risk and Harm in the Use of Psychedelics.Psychiatric research and clinical practice · 2025Article
- Article
- Excusing Psychedelics and Accommodating Psychedelics.The American journal of bioethics : AJOB · 2025Article
- Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design.Journal of eating disorders · 2024Review
- Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited?International review of psychiatry (Abingdon, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite the fact that psychedelics were proscribed from medical research half a century ago, recent, early-phase trials on psychedelics have suggested that they bring novel benefits to patients in the treatment of several mental and substance use disorders. When beneficial, the psychedelic experience is characterized by features unlike those of other psychiatric and medical treatments. These include senses of losing self-importance, ineffable knowledge, feelings of unity and connection with others and encountering 'deep' reality or God. In addition to symptom relief, psychedelic experiences often lead to significant changes in a patient's personality and worldview. Focusing on the case of psilocybin, we argue that the peculiar features of psychedelics pose certain novel risks, which warrant an enhanced informed consent process-one that is more comprehensive than what may be typical for other psychiatric medications. We highlight key issues that should be focused on during the consent process and suggest discussion prompts for enhanced consent in psychedelic psychiatry. Finally, we respond to potential objections before concluding with a discussion of ethical considerations that will arise as psychedelics proceed from highly controlled research environments into mainstream clinical psychiatry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.